RxDoctor Payments Data

Chelsea Reese, PA

Physician Assistant · Beaumont, TXNPI 1831680933

Payments from drug & device makers

$4,206in general payments, 2019–2025

Across 180 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$476
  • Mayne Pharma Commercial LLC$455
  • Regeneron Healthcare Solutions, Inc.$452
  • AbbVie$433
  • Galderma Laboratories, L.p.$380
  • UCB, Inc.$352
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,13398%
  • Education$732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,206 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$109,634
Medicare patients
455
Services billed
2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZoryveRoflumilast11$8,973
Tacrolimus17$2,535
Betamethasone Dipropionate63$2,465
Ketoconazole151$2,322
Metronidazole25$2,093
Clindamycin Phosphate52$1,795
Fluocinonide45$1,613
CiclopiroxCiclopirox Olamine54$1,525
Doxycycline Hyclate63$1,525
Triamcinolone Acetonide120$1,461
Fluorouracil16$1,193
Ciclopirox31$812
Nystatin43$792
Azelaic Acid12$782
Doxycycline Monohydrate11$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$256$8,97311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →